Aeglea BioTherapeutics Inc

+0.02 (+0.46%)
Products, Regulatory

Aeglea Biotherapeutics Announces Achievement Of Primary Endpoint In Phase 3 Study Of Pegzilarginase In Patients With Arginase 1 Deficiency

Published: 12/06/2021 12:51 GMT
Aeglea BioTherapeutics Inc (AGLE) - Aeglea Biotherapeutics Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients With Arginase 1 Deficiency.
Aeglea Bio Therapeutics Inc - 80% Plasma Arginine Reduction (primary Endpoint; P < 0.0001) Accompanied by a Positive Trend in Gmfm-e.
Aeglea Bio Therapeutics Inc - 90.5% of Patients Achieved Normal Plasma Arginine Levels.
Aeglea Bio Therapeutics Inc - Pegzilarginase Was Well-tolerated; No Discontinuations Due to Adverse Events.
Aeglea Bio Therapeutics Inc - Plan to Submit Bla in First Half of 2022.